Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma
Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 80% of...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
2014-09-01
|
| Ráidu: | Brazilian Journal of Pharmaceutical Sciences |
| Fáttát: | |
| Liŋkkat: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502014000300445&lng=en&tlng=en |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|